Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 12/20 | 1.00 |
| ▸ | TNNI3K | Q59H18 | 12/20 | 1.00 |
| ▸ | BRAF | P15056 | 10/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 0.75 |
| ▸ | CDK8 | P49336 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 2/20 | 0.65 |
| ▸ | CDK7 | P50613 | 1/20 | 0.63 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25405811 | 0.90 | KDR (0.81) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL2842603 | 0.87 | KDR (0.78) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL3831817 | 0.87 | KDR (0.77) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL17229953 | 0.85 | FLT3 (1.00) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL2847973 | 0.85 | KDR (0.74) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL2850437 | 0.84 | KDR (0.73) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL3857809 | 0.84 | KDR (0.73) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL3880675 | 0.84 | MAPK14 (0.71) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL4548923 | 0.83 | KDR (0.72) | KDRMAPK14TNNI3KBRAFFLT3 | |
| SCHEMBL2850451 | 0.81 | KDR (0.67) | KDRMAPK14TNNI3KBRAFFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592433-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | claimed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | claimed |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | claimed |
| WO-2010056907-A2 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| EP-1940844-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-07-09 | — | — | EP | claimed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | claimed |
| US-8592433-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-05-27 | — | — | US | disclosed |
| EP-1940844-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-30 | — | — | EP | disclosed |
| EP-1940844-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-30 | — | — | EP | disclosed |
| EP-1940844-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SYK, SRC, FYN | KDR 209/4885MAPK14 303/4885TNNI3K 312/4885 |
| US-20100130476-A1 | COMPOUNDS THAT INDUCE PANCREATIC BETA-CELL EXPANSION | IAPP, PNLIP, GPR119 | KDR 4824/4885MAPK14 1692/4885TNNI3K 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.